Neurological Disease News and Research RSS Feed - Neurological Disease News and Research

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

The Gladstone Institutes announces the creation of Cure Network Ventures Inc. and Cure Network Dolby Acceleration Partners, LLC, a business endeavor with Dolby Family Ventures and Evotec AG, which will focus on Alzheimer's disease. Working through Cure Network Ventures, Inc., the new company will help expedite the translation of relevant scientific discoveries from the Gladstone Institute of Neurological Disease into the development of potential therapies. [More]
Alzheimer's Association recognizes Li Gan with Inge Grundke-Iqbal Award for Alzheimer's Research

Alzheimer's Association recognizes Li Gan with Inge Grundke-Iqbal Award for Alzheimer's Research

The Alzheimer's Association is recognizing Li Gan, Ph.D., for publishing influential research on the biology of Alzheimer's disease with the Inge Grundke-Iqbal Award for Alzheimer's Research. The Award was presented today during a plenary session at the Alzheimer's Association International Conference 2015 in Washington, D.C. [More]
New monoclonal antibodies may provide blueprint for effective Alzheimer's disease treatments

New monoclonal antibodies may provide blueprint for effective Alzheimer's disease treatments

Scientists at NYU Langone Medical Center's Center for Cognitive Neurology have evidence that monoclonal antibodies they developed may provide the blueprint for effective treatments for Alzheimer's disease and other neurodegenerative diseases, such as Parkinson's disease. [More]
C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N Diagnostics and AbbVie today announced that the U.S. Food and Drug Administration has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). [More]
Rowan University, Bamboo Therapeutics partner to combat Canavan disease

Rowan University, Bamboo Therapeutics partner to combat Canavan disease

Rowan University and Bamboo Therapeutics, Inc. have entered into an asset transfer agreement to commercialize a novel gene therapy for the treatment of Canavan disease. A rare but devastating neurological disease that tragically takes a child's life by age 10, Canavan disease is one of the most common and complex degenerative cerebral diseases in infants. [More]
Next-generation tissue implant allows neuroscientists to wirelessly control neurons inside the brains of mice

Next-generation tissue implant allows neuroscientists to wirelessly control neurons inside the brains of mice

A study showed that scientists can wirelessly determine the path a mouse walks with a press of a button. Researchers at the Washington University School of Medicine, St. Louis, and University of Illinois, Urbana-Champaign, created a remote controlled, next-generation tissue implant that allows neuroscientists to inject drugs and shine lights on neurons deep inside the brains of mice. [More]
Protein delivery reagent assists neurodegeneration research

Protein delivery reagent assists neurodegeneration research

AMSBIO announces that Belgian researchers have cited use of BioPORTER Protein Delivery Reagent to introduce Tau seeds into HEK293 cells. BioPORTER Protein Delivery Reagent is a unique lipid formulation that allows direct translocation of proteins into living cells. [More]
University of Bristol-led study could provide new target for treating neurological disorders

University of Bristol-led study could provide new target for treating neurological disorders

Findings, published today [15 Jul] in Nature Communications, reveal the extent a mutation associated with autism and epilepsy plays in impairing a biochemical process in the brain. The study, led by University of Bristol researchers, could provide a new target for treating neurological disorders. [More]
Scientists redraw traditional brain map of language comprehension

Scientists redraw traditional brain map of language comprehension

For 140 years, scientists' understanding of language comprehension in the brain came from individuals with stroke. Based on language impairments caused by stroke, scientists believed a single area of the brain -- a hotdog shaped section in the temporal lobe of the left hemisphere called Wernicke's region -- was the center of language comprehension. [More]
MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis. [More]
Study opens door to deeper understanding of genetic, molecular aspects underlying sleep disorders

Study opens door to deeper understanding of genetic, molecular aspects underlying sleep disorders

Washington State University Spokane scientists have grown a tiny group of brain cells that can be induced to fall asleep, wake up and even show rebound sleep after "staying up late." [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma. [More]
Key lifestyle changes could help reduce risk of cognitive decline

Key lifestyle changes could help reduce risk of cognitive decline

The evidence is mounting: People can reduce their risk of cognitive decline by making key lifestyle changes. That is the conclusion of a new research summary published online today in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. [More]
Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone. [More]
Scientists develop human cortical spheroids

Scientists develop human cortical spheroids

A patient tormented by suicidal thoughts gives his psychiatrist a few strands of his hair. She derives stem cells from them to grow budding brain tissue harboring the secrets of his unique illness in a petri dish. She uses the information to genetically engineer a personalized treatment to correct his brain circuit functioning. Just Sci-fi? Yes, but... [More]
Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14. [More]
Study shows how people's expectation of pain affects the experience of pain

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way. [More]
Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Scientists at Mayo Clinic, Jacksonville, Florida created a novel mouse that exhibits the symptoms and neurodegeneration associated with the most common genetic forms of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), both of which are caused by a mutation in the a gene called C9ORF72. [More]
Advertisement